ERBITUX is indicated for the treatment of KRAS wild‐type, epidermal growth factor receptor (EGFR)‐expressing, metastatic colorectal cancer (mCRC) as determined by an FDA‐approved test in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first‐line treatment.
Limitations of Use : ERBITUX is not indicated for treatment of RAS-mutant colorectal cancer or when the results of the RAS mutation tests are unknown.
Please seefor ERBITUX, including Boxed Warning regarding infusion reactions.
CE HCP ISI_mCRC 15AUG2018
ERBITUX® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.